Hasija Amit 4

4 · Milestone Pharmaceuticals Inc. · Filed Jan 28, 2026

AI-generated summary of this filing

Updated Jan 29, 2026

Milestone (MIST) CFO Amit Hasija Sells Shares After PSU Vest

What Happened

Amit Hasija, Milestone Pharmaceuticals’ Chief Financial Officer and EVP of Corporate Development, had a 100,000-share performance stock unit (PSU) award vest on Dec 12, 2025 (converted to common shares) and subsequently sold shares via sell-to-cover to satisfy tax withholding. Reported sales: 58,007 shares on Dec 15, 2025 at a weighted average $2.32 ($134,576) and 12,245 shares on Jan 26, 2026 at $1.93 ($23,633). The filing also shows a conversion/exercise of 20,100 derivative shares on Jan 26, 2026 (acquired).

Key Details

Transactions reported in Form 4 filed Jan 28, 2026, covering activity from Dec 12, 2025 through Jan 26, 2026.
Dec 12, 2025: PSU award of 100,000 shares became vested/convertible (reported as award/derivative; acquisition price $0.00 for derivative).
Dec 15, 2025: Sold 58,007 shares at a weighted avg price $2.32 — proceeds ~$134,576 (F4: multiple prices aggregated).
Jan 26, 2026: Converted/exercised 20,100 derivative shares (M) and sold 12,245 shares at $1.93 — proceeds ~$23,633.
Total shares sold (reported here): 70,252 for total cash proceeds of about $158,209.
Shares owned after these transactions: not specified in the provided extract.
Notable footnotes:
- F1–F2: The 100,000 award was a PSU that vested upon FDA approval of Cardamyst (etripamil); each PSU equals one common share.
- F3: The sales were sell-to-cover transactions to satisfy income tax withholding from PSU/RSU vesting.
- F7: Certain RSUs vest in equal annual installments starting Jan 26, 2026 (illustrates ongoing vesting schedule).
- F4: Dec 15 sale price is a weighted average; the filer can provide breakdown on request.

Context

These transactions appear routine: PSUs vested (a non-cash award converted to shares) and the insider sold a portion to cover tax obligations. That is different from an open-market purchase, which some investors view as a stronger bullish signal.
The Form 4 reports conversion/exercise of derivative awards and subsequent sell-to-cover sales; this is common when equity awards vest. The filing does not, by itself, explain any change in company outlook or insider sentiment.

Form 4

Period: 2025-12-12

CFO & EVP of Corp. Development

Transactions

Award
Common Shares
[F1][F2]
2025-12-12+100,000→ 150,000 total
Sale
Common Shares
[F3][F4]
2025-12-15$2.32/sh−58,007$134,576→ 91,993 total
Exercise/Conversion
Common Shares
[F5]
2026-01-26+20,100→ 112,093 total
Sale
Common Shares
[F3][F4]
2026-01-26$1.93/sh−12,245$23,633→ 99,848 total
Award
Employee Stock Option (right to buy)
[F6]
2025-12-12+100,000→ 100,000 total
Exercise: $1.74Exp: 2034-05-06→ Common Shares (100,000 underlying)
Exercise/Conversion
Restricted Stock Units
[F5][F7]
2026-01-26−20,100→ 60,300 total
→ Common Shares (20,100 underlying)

Footnotes (7)

[F1]Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil).
[F2]Each PSU represents a contingent right to receive one common share.
[F3]Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]Each RSU represents a contingent right to receive one common share.
[F6]50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date.
[F7]One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.

Signature

/s/ Joseph Oliveto, Attorney-in-Fact|2026-01-28

1 file